The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The potential of the CELMoD golcadomide in large B-cell lymphoma
In this video, Marc Hoffmann, MD, University of Kansas Medical Center, Kansas City, KS, briefly discusses the potential role of golcadomide, a cereblon E3 ligase modulatory drug (CELMoD), in the treatment of large B-cell lymphoma (LBCL), highlighting its efficacy in both the frontline and relapsed/refractory (R/R) setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think, we presented about six months ago at ASH the longer-term follow-up of the single-agent golcadomide and the golcadomide with rituximab data in refractory large cell. And there were some durable long-term responders. The response rates are quite high. I think that the drug works in both the frontline and relapsed/refractory setting. I think, ideally there’s a large randomized phase three study of Golcadamide plus R-CHOP versus R-CHOP that completed accrual over six months ago and that we eagerly anticipate the results of that...
So I think, we presented about six months ago at ASH the longer-term follow-up of the single-agent golcadomide and the golcadomide with rituximab data in refractory large cell. And there were some durable long-term responders. The response rates are quite high. I think that the drug works in both the frontline and relapsed/refractory setting. I think, ideally there’s a large randomized phase three study of Golcadamide plus R-CHOP versus R-CHOP that completed accrual over six months ago and that we eagerly anticipate the results of that. So hopefully there will be a frontline indication and a role for these drugs in the near future, which would indicate that we’re curing more patients in the frontline with large cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
